New Alzheimer’s Drugs Offer Subtle Benefits—With Real Risks

Lecanemab received accelerated approval in January of this year after a Phase III trial showed that it modestly slowed cognitive decline.

Eli Lilly's drug, donanemab, appears to slow de a few years more—by about 0.7 points.

Atotal ofsix patients may have died as a result of si Rob Howard from anti-amyloid drugs.

Amyloid-tar University College London tly cause the brain to swell and bleed.

Poor pati more than 20.”Those s, and those without family or social support might not be able to try the drugs.

The idea that a life with Alzheimer’s is of so little value as to make any treatment worthwhile may be widespread, but it eras June 2021 ch the US Food and Drug Administration ir FDA t lead.

“People with mild dementia, even moderate dementia, can live extremely fulfilling, happy lives,” Howard says. years Howard donanemab January of this year NxlGi">a decade Howard the Clinical Dementia Rating tT CDR __NxlGi">Hail Mary Cli daily ns Schneider 0.5 lGi">the National Health Service May yF Eli Lilly ightText__NxlGi">UK about 0.7 pan> next month FDA 0.5- >FDA< 0.7 an> CDR _highLightText__NxlGi">almost half half lGi">the University of Pennsylvania Emily Largent Medicare US one xlGi">Hispanic CDR tT 0.5 __NxlGi">Black US every few months one _NxlGi">a year 100,000 CDR ummaryFeed_highLig one ext__NxlGi">a hundred Julio Rojas /span> the University of California, o San Francisco liforniahalf Lon Schneider< several additional months aryFeed_highLightText__NxlGi">six San Franci CDR Eli Lilly’s ryFeed_highLightText__NxlGi">the University 0.7 California, Maria Glymour about 35 percent ummaryFeed_highLightTe 35 percent >FDA donanemab 18 months 35 percent s="summaryFeed_highLightText__NxlGi">Howard years later 35 percent